Lung cancer staging: proteomics.


Journal Article (Review)

The results of ACOSOG Z4031 may provide landmark information for the use of proteomic profiling to diagnose lung cancer noninvasively and to provide more accurate predictions of survival. Although the technological developments allowing generalized use of proteomic and genomic analyses are relatively recent, major progress in understanding the molecular basis of lung cancer has been made. Predicting survival is only the first step in the use of proteomics. If a reliable protein profile can be identified that is associated with poor prognosis, these proteins can then be identified and become therapeutic targets. It is not difficult to envision a day when a simple blood test will diagnose a lung cancer, perhaps even before it is clinically apparent, and, at the same time, identify the chemotherapeutic agents to which the tumor is sensitive, allowing individually directed treatment.

Full Text

Duke Authors

Cited Authors

  • Harpole, DH; Meyerson, SL

Published Date

  • November 2006

Published In

Volume / Issue

  • 16 / 4

Start / End Page

  • 339 - 343

PubMed ID

  • 17240821

Pubmed Central ID

  • 17240821

International Standard Serial Number (ISSN)

  • 1547-4127

Digital Object Identifier (DOI)

  • 10.1016/j.thorsurg.2006.10.001


  • eng

Conference Location

  • United States